These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3478328)

  • 1. In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem.
    Van der Auwera P; Ernst F; Grenier P; Glupczynski Y; Husson M; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):179-89. PubMed ID: 3478328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.
    Neu HC; Chin NX; Labthavikul P
    J Antimicrob Chemother; 1985 Sep; 16(3):305-13. PubMed ID: 2997100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
    Chin NX; Neu HC
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():95-101. PubMed ID: 2786520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of the new penems FCE 22101 and FCE 24362 alone or in combination with aminoglycosides against streptococci isolated from patients with endocarditis.
    Dornbusch K; Henning C; Lindén E
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():109-17. PubMed ID: 2732133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of a new penem FCE 22101.
    Hoban DJ
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():53-7. PubMed ID: 2786518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex.
    Inderlied CB; Lancero MG; Young LS
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():85-99. PubMed ID: 2808217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of imipenem against gram-positive and gram-negative aerobic bacteria from clinical isolates.
    Bastianini L; Sposini T; Bartoli A; Marconi P
    Microbiologica; 1988 Apr; 11(2):137-42. PubMed ID: 3165489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative inhibitory and bactericidal activities of FCE 22101 against gram-positive cocci and anaerobes in vitro.
    Maskell JP; Tang T; Asad S; Williams JD
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():65-74. PubMed ID: 2732145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.
    Barry AL; Aldridge KE; Allen SD; Fuchs PC; Gerlach EH; Jones RN; Pfaller MA
    Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):794-8. PubMed ID: 3145868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
    Bretonnière C; Maitte A; Caillon J; Potel G; Boutoille D; Jacqueline C; Guitton C
    J Antibiot (Tokyo); 2016 Nov; 69(11):806-810. PubMed ID: 27025352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests.
    Barry AL; Jones RN; Thornsberry C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():17-30. PubMed ID: 2732139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K; Ishida A; Chinzei T
    Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
    Hofer B; Dantier C; Gebhardt K; Desarbre E; Schmitt-Hoffmann A; Page MG
    J Antimicrob Chemother; 2013 May; 68(5):1120-9. PubMed ID: 23344577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro interactions of FCE 22101 with aminoglycosides against gram-negative rods.
    Said AA; Livermore DM
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():103-8. PubMed ID: 2732132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
    Christiansen KJ; Ip M; Ker HB; Mendoza M; Hsu L; Kiratisin P; Chongthaleong A; Redjeki IS; Quintana A; Flamm R; Garcia J; Cassettari M; Cooper D; Okolo P; Morrissey I
    Int J Antimicrob Agents; 2010 Dec; 36(6):501-6. PubMed ID: 20869212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of imipenem towards gram-negative bacilli.
    Speciale A; Caccamo F; Pellegrino MB; Blandino G; Nicoletti G
    Chemioterapia; 1986 Oct; 5(5):291-6. PubMed ID: 3466723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.